--- title: "Evofem Biosciences (EVFM) news: convertible notes and merger" url: "https://aibio.space/companies/evofem-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EVFM convertible notes and merger news: Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026. Evofem Biosciences, Inc." --- EVFM Evofem Biosciences, Inc. OTC · United States # Evofem Biosciences (EVFM) news EVFM convertible notes and merger news Financings · 2026-10-15 ## [Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026](https://aibio.space/news/evofem-biosciences-pushes-adjuvant-note-maturity-december-1-2026/) Evofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000. ## Latest Evofem Biosciences news 1. 2026-09-23 Company Updates [Evofem adds a second manufacturer for PHEXX](https://aibio.space/news/evofem-adds-second-manufacturer-phexx/) Subject to regulatory approval, the new source is expected to reduce unit costs by 40% or more. Evofem expects to submit a supplemental NDA in mid-2027. 2. 2026-07-08 Debt Financing [Evofem Biosciences issues $706,304 subordinated note to HUB Cyber Security](https://aibio.space/news/evofem-biosciences-issues-706-304-subordinated-note-hub-cyber-security/) Evofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126. 3. 2026-05-18 Company Updates [Evofem reports first quarter 2026 net loss of $5.5 million](https://aibio.space/news/evofem-reports-first-quarter-2026-net-loss-5-5-million/) Net sales were $0.9 million, up from $0.8 million a year earlier. The CEO said the company looks forward to non-dilutive capital from ex-U.S. partnerships in 2026. 4. 2026-04-27 Company Updates [Evofem signs exclusive SOLOSEC distribution deal for sub-Saharan Africa](https://aibio.space/news/evofem-signs-exclusive-solosec-distribution-deal-sub-saharan-africa/) Clovis Davis Pharmaceuticals will lead distribution, promotion, marketing and sales of SOLOSEC in the territory. The release is dated April 27, 2026. 5. 2026-04-10 Distress [Evofem amends Adjuvant convertible note terms and payment date](https://aibio.space/news/evofem-amends-adjuvant-convertible-note-terms-payment-date/) The Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent. 6. 2025-08-26 Mergers [Evofem signs sixth amendment to Aditxt merger agreement](https://aibio.space/news/evofem-signs-sixth-amendment-aditxt-merger-agreement/) Evofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought. ## Evofem Biosciences at a glance - **Ticker**: EVFM - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $285,000 ### Related companies - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) OTC: MCET - [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN - [Septerna](https://aibio.space/companies/septerna/) NASDAQ: SEPN - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) NASDAQ: APVO - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) NASDAQ: ALDX - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) AMEX: CLDI - [HCW Biologics](https://aibio.space/companies/hcw-biologics/) NASDAQ: HCWB ### Also on OTC - [ProText Mobility](https://aibio.space/companies/protext-mobility/) TXTM - [HST Global](https://aibio.space/companies/hst-global/) HSTC - [Electromedical Technologies](https://aibio.space/companies/electromedical-technologies/) EMED - [POSITRON CORP](https://aibio.space/companies/positron/) POSC - [BIOSTAR PHARMACEUTICALS INC](https://aibio.space/companies/biostar-pharmaceuticals/) BSPM - [Scopus Biopharma](https://aibio.space/companies/scopus-biopharma/) SCPS ## What Evofem Biosciences does Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its first commercial product, PHEXX, is described as the first and only non-hormonal prescription contraceptive vaginal gel. The FDA approved PHEXX on May 22, 2020 for the prevention of pregnancy, and it launched in the U.S. in September 2020. In July 2024 the company acquired global rights to SOLOSEC, an FDA-approved single-dose oral antimicrobial agent for bacterial vaginosis and trichomoniasis, and relaunched it in November 2024. Outside the U.S., the company licensed commercial rights to PHEXX and SOLOSEC in the Middle East and North Africa to Pharma 1 Drug Store, LLC in July 2024 and May 2025. Pharma 1 filed for regulatory approval of PHEXX in the United Arab Emirates in June 2025 and of SOLOSEC in September 2025. The company's stated strategy includes lowering manufacturing costs and opportunistically acquiring or in-licensing additional launch-ready products. | Product or program | What it is | Stage | |---|---|---| | PHEXX | Non-hormonal prescription contraceptive vaginal gel | FDA approved May 22, 2020; launched in the U.S. September 2020 | | SOLOSEC | Single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis | FDA-approved; relaunched November 2024 | Summarised from the company's [10-K filed Mar 11, 2026](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm). ## Evofem Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1618835/000164117225000188/) | | Net income (loss) | [$391,000](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | [-$8.9 million](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | | Cash from operations | [-$2.0 million](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | [-$3.9 million](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | | Cash and equivalents | [$578,000](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | [$741,000](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $285,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Evofem Biosciences Has Evofem Biosciences sold convertible notes? Our latest story on this, dated Oct 15, 2026: "Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evofem-biosciences-pushes-adjuvant-note-maturity-december-1-2026/). Is Evofem Biosciences involved in a merger or acquisition? Our latest story on this, dated Aug 26, 2025: "Evofem signs sixth amendment to Aditxt merger agreement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evofem-signs-sixth-amendment-aditxt-merger-agreement/). What is the ticker symbol of Evofem Biosciences? Evofem Biosciences, Inc. trades under the ticker EVFM on OTC. Where is Evofem Biosciences listed? Evofem Biosciences, Inc. is listed on OTC. What is the SEC CIK of Evofem Biosciences? The SEC Central Index Key (CIK) for Evofem Biosciences, Inc. is 1618835. Its filings are on SEC EDGAR. How many shares does Evofem Biosciences have outstanding? 132,530,081 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Evofem Biosciences listed under? Our directory records Evofem Biosciences, Inc. under United States. What does Evofem Biosciences do? Our directory classifies Evofem Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Evofem Biosciences? The ISIN recorded for Evofem Biosciences, Inc. is US30048L3024. Does aibio.space cover Evofem Biosciences? aibio.space lists Evofem Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Evofem Biosciences incorporated? SEC records list its state or country of incorporation as DE. What does Evofem Biosciences develop? Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its first commercial product, PHEXX, is described as the first and only non-hormonal prescription contraceptive vaginal gel. What is PHEXX from Evofem Biosciences? PHEXX: Non-hormonal prescription contraceptive vaginal gel Stage: FDA approved May 22, 2020; launched in the U.S. September 2020. What is SOLOSEC from Evofem Biosciences? SOLOSEC: Single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis Stage: FDA-approved; relaunched November 2024. Is Evofem Biosciences profitable? Evofem Biosciences, Inc. reported net income of $391,000 for the fiscal year ended Dec 31, 2025, and used $2.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Evofem Biosciences Members talk about Evofem Biosciences (EVFM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Evofem Biosciences, newest first. Each line links the filing it comes from. 1. 2026-10-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm) 2. 2026-04-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/form8-k.htm) 3. 2026-03-19 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315226011613/form8-k.htm) 4. 2025-11-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225025172/form8-k.htm) 5. 2025-10-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225020062/formdef14a.htm) 6. 2025-10-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225018687/ex99-1.htm) 7. 2025-10-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225018688/formpre14a.htm) 8. 2025-10-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/form8-k.htm) 9. 2025-08-26 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/form8-k.htm) 10. 2025-03-26 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000164117225000742/ex99-1.htm) 11. 2025-01-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315225001682/form8-k.htm) 12. 2024-10-31 Distress Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,1.02,2.04,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1618835/000149315224043241/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:EVFM on TradingView](https://www.tradingview.com/symbols/OTC-EVFM/). ## SEC filings and registration - **SEC name**: Evofem Biosciences, Inc. - **CIK**: 1618835 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: EVFM (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 12400 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130 - **Phone**: (858) 550-1900 - **Shares outstanding**: 132,530,081 as of 2026-08-12 (10-Q filed 2026-08-14) - **Former names**: Neothetics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/form8-k.htm) filed 2026-09-23 - [10-Q](https://www.sec.gov/Archives/edgar/data/1618835/000149315226038328/form10-q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226033910/form8-k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226033184/form8-k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/form8-k.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1618835/000149315226023928/form10-q.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/form8-k.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001618835), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Evofem Biosciences, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker EVFM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Evofem Biosciences, Inc. - **Ticker**: EVFM - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US30048L3024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-EVFM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/evofem-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Evofem Biosciences (EVFM) news: convertible notes and merger", 2026-10-31, https://aibio.space/companies/evofem-biosciences/